Patricia Andrews Biography and Net Worth

Director of GlycoMimetics

Ms. Andrews has been a member of the GlycoMimetics board since June 2017. Ms. Andrews is the CEO of Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage research and development biopharmaceutical company, and Global Head of Oncology and an Executive Officer for Sumitomo Dainippon Pharma Co., Ltd. Prior to joining this organization in 2013, she was Executive Vice President and Chief Commercial Officer at Incyte for four years, where she established the commercial organization for the launch of its first-in-class, first-in-disease oncology product Jakafi®. She was also responsible for business development and completed multiple significant product licensing deals for Incyte. Ms. Andrews held increasing leadership positions at Pfizer from 1991-2008, with her final role being Vice President and General Manager of the U.S. Oncology Business Unit. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.

How do I contact Patricia S. Andrews?: The corporate mailing address for Ms. Andrews and other GlycoMimetics executives is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. GlycoMimetics can also be reached via phone at (240) 243-1201 and via email at [email protected]. Learn More on Patricia S. Andrews' contact information.
Has Patricia S. Andrews been buying or selling shares of GlycoMimetics?: Patricia S. Andrews has not been actively trading shares of GlycoMimetics during the last quarter. Most recently, on Tuesday, November 16th, Patricia S. Andrews bought 400 shares of GlycoMimetics stock. The stock was acquired at an average cost of $205.00 per share, with a total value of $82,000.00. Learn More on Patricia S. Andrews' trading history.

Patricia S. Andrews Insider Trading History at GlycoMimetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/16/2021	Buy	400	$205.00	$82,000.00

Patricia S. Andrews Buying and Selling Activity at GlycoMimetics

GlycoMimetics Company Overview

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Today's Range

Now: $0.16

$0.15

$0.17

50 Day Range

MA: $13.48

$0.16

$27.47

2 Week Range

Now: $0.16

$14.06

$63.00

Volume

1,049,686 shs

Average Volume

67,672 shs

Market Capitalization

$10.00 million

P/E Ratio

N/A

Dividend Yield